On October 16, 2020, the Minister of Education and Science of the Republic of Kazakhstan Aimagambetov Askhat Kanatovich paid a working visit to the National Scientific Center for Phthisiopulmonology of the Ministry of Health of the Republic of Kazakhstan, designated a clinical base for conducting phase I/II clinical trials of QazCovid-in® – COVID-19 inactivated vaccine.
During the working visit, the Minister of Education and Science of the Republic of Kazakhstan Aimagambetov A.K. a meeting was held with the top management and medical workers of the National Scientific Center for Phthisiopulmonology of the Ministry of Health of the Republic of Kazakhstan, the main and responsible researchers for the phase I/II clinical trials of the QazCovid-in® – COVID-19 inactivated vaccine, carried out within the framework of the scientific and technical program “Development of COVID-19 coronavirus infection vaccine”, which is carried out by the Scientific Research Institute of Biological Safety Problems of the Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan
During the working meeting, the Minister of Education and Science of the Republic of Kazakhstan Aimagambetov A.K. got acquainted with the course of organization, conduct and the current state of the phase I/II clinical trials of QazCovid-in® – COVID-19 inactivated vaccine.
Minister of Education and Science of the Republic of Kazakhstan Aimagambetov A.K. said that the development of a COVID-19 domestic vaccine is under constant control of the Government of the Republic of Kazakhstan. The scientific and technical program “Development of COVID-19 coronavirus infection vaccine” was approved by the Decree of the Government of the Republic of Kazakhstan. For the successful implementation of this STP, the Ministry of Education and Science of the Republic of Kazakhstan allocated additional funds for the material and technical equipment of the RIBSP.
Minister of Education and Science of the Republic of Kazakhstan Aimagambetov A.K. wished all performers and participants of the phase I/II clinical trials of QazCovid-in® – COVID-19 inactivated vaccine the successful completion of the clinical trial and the earliest possible receipt of an effective vaccine in order to ensure the biological safety of the Republic of Kazakhstan!